Table 1.
Characteristics of included studies
| Author | Year | Location | Design | Data | Population, n | Tenofovir use | Entecavir use | Age, year | Gender | Length of follow-up, year |
|---|---|---|---|---|---|---|---|---|---|---|
| Yip et al. [9] | 2019 | China | Retrospective cohort | CDARS | 5,836 | 1,200 | 4,636 | 52 | Both | 3.6 |
| Lee et al. [12] | 2019 | Korea | Retrospective cohort | Liver units of the Catholic University of Korea | 2,740 | 1,370 | 1,370 | 47 | Both | 3.9 |
| Kim et al. [11] | 2019 | Korea | Retrospective cohort | Four centers | 2,556 | 1,278 | 1,278 | 48 | Both | 4.9 |
| Hsu et al. [21] | 2019 | Multi countries | Retrospective cohort | Registry database of the REAL-B | 1,040 | 520 | 520 | 50 | Both | 4.1 |
| Choi et al. [18] | 2019 | Korea | Retrospective cohort | Asian Medical Center | 21,846 | 10,923 | 10,923 | 48 | Both | 3.3 |
| Kim et al. [22] | 2018 | Korea | Retrospective cohort | Ulsan University Hospital | 1,325 | 604 | 721 | 51 | Both | 5 |
| Tsai et al. [20] | 2017 | Taiwan | Retrospective cohort | Chang Gung Memorial Hospital | 442 | 83 | 359 | 56 | Both | 3.2 |
CDARS, Clinical Data Analysis and Reporting System.